On Monday the announcement came from Global Health Ventures, Inc., that they would be developing a sublingual version of migraine drug telcagepant.
Telcagepant, a calcitonin gene-related peptide receptor antagonist, has had a rocky beginning. Hailed in 2008 as the beginning of a new era in migraine treatment, the trials faltered over concerns about preventative use. Researchers were concerned when some patients developed high levels of liver enzymes (transaminases).
The drug’s developer, Merck, was cautious about the continued development of the drug, even as an abortive. Then, earlier this year, they announced that they would continue safety trials.
This past Monday, Global Health Ventures in Vancouver Canada, expressed their confidence in the future of telcagepant by announcing their commitment to developing a sublingual version. A special type of sublingual technology is one of the specialties of the company.
Global Health Ventures Inc. (the “Company”), a Specialty Pharma with focus on sublingual drug delivery, is pleased to announce that, it has initiated the development of a sublingual formulation of Telcagepant. Telcagepant is believed to be a powerful anti-migraine drug developed by Merck & Company. The drug blocks the recently discovered clacitonin-gene related hormone receptor (CGRP), a powerful vasodilator protein believed to be a key player in migraine.